Treatment of latent tuberculosis infection

Therapeutic Advances in Respiratory Disease

Volumn 7, Issue 6, 2013, Pages 351-356

  Parekh, Madhavi J ^a   Schluger, Neil W ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Department of Medicine   (United States)

Author keywords

infection; isoniazid; latent; rifampin; rifapentine; Tuberculosis

Indexed keywords

INFECTION; ISONIAZID; LATENT; RIFAMPIN; RIFAPENTINE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; RIFAMPIN; TIME FACTORS; TUBERCULOSIS;

AMINOTRANSFERASE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DIRECTLY OBSERVED THERAPY; DISEASE ASSOCIATION; DRUG SELF ADMINISTRATION; EMPLOYMENT; FOLLOW UP; HEALTH CARE FACILITY; HIGH RISK POPULATION; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; LEUKOPENIA; LIVER TOXICITY; MALNUTRITION; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; RISK REDUCTION; SUBSTANCE ABUSE; THROMBOCYTOPENIA; TREATMENT DURATION; TUBERCULIN TEST;

EID: 84887833220     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465813503028     Document Type: Article

References (35)

1. Abu-Raddad L. Sabatelli L. Achterberg J. Sugimoto J. Longini I. Jr Dye C. (2009) Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 106: 13980-13985.
2. Aichelburg M. Rieger A. Breitenecker F. Pfistershammer K. Tittes J. Eltz S. (2009) Detection and prediction of active tuberculosis disease by whole-blood interferon-gamma release assay in HIV-1 infected individuals. Clin Infect Dis 48, 954-962.
3. Akolo C. Adetifa I. Shepperd S. Volmink J. (2010) Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 1: CD000171.
4. American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: S221-S247.
5. Aspler A. Long R. Trajman A. Dion M. Khan K. Schwartzman K. (2010) Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 65: 582-587.
6. Bennett D. Courval J. Onorato I. Agerton T. Gibson J. Lambert L. (2007) Prevalence of tuberculosis infection in the United States population: the National Health and Nutrition Examination Survey, 1999–2000. Am J Respir Critical Care Med 177: 348-355.
7. Bucher H. Griffith L. Guyatt G. Sudre P. Naef M. Sendi P. (1999) Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 13: 501-507.
8. Centers for Disease Control and Prevention (2010) Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection ’ United States, 2010. MMWR 59: RR-5.
9. Centers for Disease Control and Prevention (2011) Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR 60: 1650-1653.
10. Clark S. Martin S. Pozniak A. Steel A. Ward B. Dunning J. (2007) Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 150: 238-244.
11. Comstock G. (1993) How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 3: 847-850.
12. Ena J. Valls V. (2005) Short-course therapy with rifampin plus isoniazid compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 40: 670-676.
13. Farhat M. Greenaway C. Pai M. Menzies D. (2006) False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 10: 1192-1204.
14. Geng E. Kreiswirth B. River C. Li J. Burzynski J. Della Latta P. (2002) Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 346: 1453-1458.
15. Gordin F. Chaisson R. Matts J. Miller C. de Lourdes Garcia M. Hafner R. (2000) Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in hiv-infected persons: an international randomized trial. JAMA 283: 1445-1450.
16. Grant A. Charalambous S. Fielding K. Day J. Corbett E. Chaisson R. (2005) Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 293: 2719-2725.
17. Halsey N. Coberly J. Desormeaux J Losikoff P. Atkinson J. Moulton L. (1998) Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351: 786-792.
18. Hirsch-Moverman Y. Bethel J. Colson P. Franks J. El-Sadr W. (2010) Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis 14: 1104-1111.
19. Hong Kong Chest Service/Tuberculosis Research Centre (1992) A double-blind placebo controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 145: 36-41.
20. Horsburgh C. (2004) Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 20: 2060-2067.
21. Horsburgh C. Golberg S. Bethel J. Chen S. Colson P. Hirsch-Moverman Y. (2010) Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 137: 401-409.
22. Horsburgh C. Rubin E. (2011) Latent tuberculosis infection in the United States. N Engl J Med 364: 1441-1448.
23. International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 60: 555-564.
24. Jasmer R. Saukkonen J. Blumberg H. Daley C. Bernardo J. Vittinghoff E. (2002) Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 137: 640-647.
25. Kopanoff D. Snider D. Caras G. (1979) Isoniazid related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117: 991-1001.
26. Li J. Munsiff S. Tarantino T. Dorsinville M. (2010) Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis 14: e292-e297.
27. Martinson N. Barnes G. Moulton L. Msandiwa R. Hausler H. Ram M. (2011) New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 365: 11-20.
28. Menzies D. Dion M. Rabinovitch B. Mannix S. Brassard P. Schwartzman K. (2004) Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 170: 445-449.
29. Menzies D. Long R. Trajman A. Dion M. Yang J. Al Jahdali H. (2008) Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 149: 689-697.
30. Pai M. Zwerling A. Menzies D. (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149: 177-184.
31. Pape J. Jean S. Ho J. Hafner A. Johnson W. (1993) Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342: 268-272.
32. Sterling T. Bethel J. Goldberg S. Weinfurter P. Yun L. Horsburg C. (2003) The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 173: 927-931.
33. Sterling T. Villarino M. Borisov A. Shang N. Gorin F. Sliven-Sizemore E. (2011) Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365: 2155-2166.
34. Whalen C. Johnson J. Okwera A. Hom D. Huebner R. Mugyenyi P. (1997) A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 337: 801-808.
35. World Health Organization (2012) Global Tuberculosis Control: WHO Report 2012. Geneva: World Health Organization.